Influenza going up in the UK. For those involved in the RECOVERY trial of influenza treatments - please try to enrol patients. If this season is short and sharp, we will have a limited time window for recruitment.
So, in the end, both France and Britain voted against the far-right.
Doesn't mean the threat is gone, but pay attention to the center, center left, green and center right voters who are still the majority in Europe, everywhere except Hungary.
Ending Tuberculosis is within reach. So why are millions still dying? A brilliant article on the challenges (and opportunities) of ending TB and saving a hundred million lives over the next century. https://t.co/dk9GrnOeTn
Immortal time bias: a 🧵
When I was an infectious diseases intern, I attended @justin_denholm, Dr Street & @syctong's #VIDSJC journal club, we discussed this @JAMAInternalMed paper: Association of Evidence-Based Care w Mortality in staph aureus bacteremia https://t.co/EP4B6UPuxj
Scandalous that so little is done about diseases like monkeypox until high income countries are affected.
But there has been international cooperation to try to improve the situation:
See BMJ article https://t.co/R6yz6hIGtc
Plus a clinical trial has started in DRC NCT05559099
What's the fastest way to diagnose Ebola Virus Disease in low-resource settings? New paper in CMI
#Ebola#EbolaOutbreakUG#EbolaOutbreak
The Diagnostic Accuracy of Rapid Diagnostic Tests for Ebola Virus Disease: a Systematic Review https://t.co/Oxc9WK7mQ3
Fantastic opportunity for a dynamic & passionate individual to join @PSIOxford. Nipah virus infection has a fatality rate of up to 75%. Come work with us to transform the way we prevent & treat this important high-threat infectious disease @PeterHorby@OutbreakJake@ERGO_Horby
In this trial, a restrictive approach to intravenous fluid administration in critically ill patients with septic shock did not reduce mortality. #CCR22 https://t.co/UfY1936Qwb
NEW @OpenSAFELY paper KLAXON
Comparing sotrovimab and molnupiravir for prevention of severe outcomes in non-hospitalised patients with COVID-19.
https://t.co/bfVVEpMes7
Preprint not yet peer reviewed, under review at a journal, sharing for info.
INTERESTING THINGS THREAD: 1/n
Major boost for Oxford’s mission to counter future pandemic threats
This extremely generous gift from the Moh Family Foundation launches the Pandemic Sciences Institute as a global asset to strengthen health security for all @PSIOxford
https://t.co/zLJQjLSaed
New RECOVERY result: Baricitinib
8156 patients randomly allocated to receive usual care plus baricitinib versus usual care alone.
28-day mortality lower in patients allocated baricitinib: 513/4148 (12%) vs 546/4008 (14%) (age-adjusted rate ratio 0.87; 95% CI 0.77-0.98; p=0.026)
📢Two of our students studying for the MSc in Evidence-Based Health Care have won the prestigious EBHC Dissertation Prize for their outstanding dissertations. Many congratulations to @DrewDagens1 & Stella Vieth!🌟🌟Details:👇 @cebmOxford
https://t.co/4lMWIkOtkw